Incor Lifesciences will use State of the Art Technology and AI based Tools as applicable to achieve our mission.
A pharma company with dedicated laboratories situated at the Indian Institute of Chemical Technology, Hyderabad, and also the corporate headquarters in the city. The integral unit employs advanced Artificial Intelligence for chemical process design and continuous flow manufacturing.
Incor Lifesciences India also has over 5 projects that are currently running along with the production of 9+ products. With a bunch of like-minded peers, they are driving steadily towards massive progression in the field.
Incor Lifesciences will utilize AI tools to develop routes for small molecule APIs, peptides & co-crystals leading to the manufacturing of commercially viable drug substances which not only can lower costs by 20% to 40 % but also reduce time to market.
During the process we will strive to achieve global cost parity and environmental superiority with existing producers throughout the world establishing Incor Lifesciences as a leader in the API industry.
Incor Lifesciences will also adopt Continuous Flow Chemistry as it offers the advantage of expediting the development time by eliminating the scaleup process which enables reduction in the development process by weeks/months.
Continuous Processing to realize up to 50% reduction in manufacturing costs from reduced capital/ labor & environmental costs
With continuous manufacture you engineer the process to reduce capital cost, labor cost, Solvent usage and with better control; Making it a GREEN ENV.
We aspire to continue contributing towards enriching the quality of life on a global scale. At Incor, we are steadily steering towards the creation of innovative pharmaceuticals with diverse medical needs. We also want to do this by upholding the highest of ethical standards as we go about touching human lives.
Incor Lifesciences will emphasize exploiting emerging technical trends in the pharma industry so that within two years we can begin selling high value-added peptides & Co-Crystals which will have clinically enhanced results.
Incor Lifesciences will develop Co-Crystals for 505(b)2 for the US market, possibly providing the basis for entering the market with finished dosage form products.
We intend to offer the next-generation small molecule APIs, Peptide & Co-Crystal technologies providing access to customers and US patients a product and cost based competitive advantage.
As a company, we are looked up to as frontiers in the pharmaceutical segment and we strive to set new standards for the medicine world to follow each day.